Nuclear medicine delivering improvements in diagnosis and treatment of cancer

November 26, 2021

Register for the next ANSTO x Science Meets Business Innovation Series exploring how nuclear is medicine delivering improvements in human health and the treatment and diagnosis of cancer.

Register for the next ANSTO x Science Meets Business Innovation Series to explore how nuclear medicine is delivering improvements in human health and the treatment and diagnosis of cancer, Wednesday 8 December 2021.

Although many people might know that ANSTO produces nuclear medicines, including the most commonly used diagnostic imaging agent, they may not be aware of the other research and development activities in nuclear medicine that benefit human health.

World-leading nuclear science, combined with expertise of ANSTO staff and collaborators in academia and industry, are at the cutting-edge of investigations into the origin of diseases, like cancer. State-of-the-art nuclear research is finding improved methods to detect, diagnose and monitor the progression of disease and develop therapies to treat disease.

At this free online event you’ll meet experts who are at the forefront of nuclear medicine and research and who are working to save lives.

Meet the Expert Panel

Science broadcaster Lee Constable will host a discussion with:

Rosanne Robinson: Rosanne Robinson is CEO, Detection & Imaging and General Manager, Business Development & Commercialisation at ANSTO. Rosanne is an innovation and research commercialisation professional with broad experience cultivating the interface of science and industry. She has extensive experience in the commercialisation of cutting-edge technology across a range of fields, developing engagement strategies and international commercial partnerships that deliver value to collaborators and customers.

Benjamin Fraser: Ben is a Radiotracer Methods and Organic Chemistry Task Leader, Health Research at ANSTO. He has over 15 years of experience in organic chemistry and radiochemistry and leads the organic chemistry capability and the radiotracer methods research theme in ANSTO LifeSciences.

Ben’s role includes management of the synthetic chemistry laboratories, development of new radiolabeling methods, directing staff on chemical synthesis projects and managing the supply of radiolabelling precursors and standards for the ANSTO radiochemistry team. Ben holds adjunct research appointments at both The University of New South Wales and Monash University.

Professor Geoff Currie, AM: Geoff is a Professor in Nuclear Medicine, Charles Sturt University. Geoff has a bachelor’s degree in pharmacy, a master’s degree in medical radiation science (nuclear medicine), a master’s degree in applied management (health), a master’s degree in business administration (MBA), and a doctor of philosophy (PhD).

Geoff has more than 180 peer-reviewed journal papers, author of two books, author of five book chapters, presented 175 conference presentations, 65 invited speaker presentations, and as a reviewer for 25 international journals. Geoff is an adjunct Professor in Radiology at Baylor College of Medicine in Houston Texas. On Australia Day 2020, Geoff was awarded Member of the Order of Australia (AM) in recognition of his contribution to nuclear medicine and medical radiation science.

Dr Matt Harris: Matt is the founder, former CEO (2010-2019) and currently Chief Scientific Officer at Clarity Pharmaceuticals. Matt has approximately 20 years of combined experience in cancer research, nuclear medicine and business and has a PhD in cancer research from the Australian National University. Matt brings expertise in biotechnology, radiopharmaceuticals, academic research and investment to Clarity and focuses on developing the technology behind Clarity’s products.

Innovation in Nuclear Medicines and Health: 12pm (AEDT) Wednesday 8 Dec 2021 / via Zoom.

This webinar is FREE to attend and registration is essential. Secure your spot by clicking the button above.

The ANSTO Innovation Series

The ANSTO Innovation Series is a new virtual meet-up that focuses on the key capacities of ANSTO’s people, partners and facilities and how they are meeting global challenges in sustainable industries, medicine, advanced manufacturing and in accelerating small business.

Delivered as a quarterly webinar, the ANSTO Innovation Series features an expert panel exploring the latest science, industry and start-up opportunities, including innovations in energy storage, nuclear medicine and health, engineering new materials and accelerating deep tech business.

The ANSTO Innovation Series is produced in partnership with STEM-specialist publishers, Refraction Media, publishers of Science Meets Business, and hosted by leading science journalist, Lee Constable.

About ANSTO

The Australian Nuclear Science and Technology Organisation (ANSTO) is the home of Australia’s most significant national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.

ANSTO researchers work on global science and technology challenges, and operate landmark research infrastructure including one of the world’s most modern nuclear research reactors, OPAL; as well as a comprehensive suite of neutron beam instruments at the Australian Centre for Neutron Scattering; the Australian Synchrotron; the National Imaging Facility Research Cyclotron; and the Centre for Accelerator Science. ANSTO also hosts the nandin innovation centre, one of Australia’s few deep technology hubs facilitating industry engagement and research translation.

Subscribe to our regular innovation and research news updates to get notification of the webinars.

Related stories

2 thoughts on “Fresh opportunities”

  1. His speech seemed not delivered much from science, he sounded more like politician; his answers to jurnalysts’ questions have not made impression on jurnalyst and viewers. CSRO misses opportunity to address vital areas for Australia during his mandate.

Leave a Reply

Your email address will not be published. Required fields are marked *